drugset / Trial / NCT03939923

Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery

NCT03939923

Phase 4 Completed 84 enrolled West Virginia University
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to examine whether the use of Sugammadex will reduce time from reversal to extubation and improve other post extubation outcomes in Coronary artery bypass grafting patients. This study is a prospective, clinical interventional, randomized single blinded single-center design. The nurses in the cardiac intensive care unit will be blinded to treatment allocation (Group 1 or 2).

Timeline

Start
2019-05-01
Primary completion
2021-07-30
Completion
2021-07-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glycopyrrolate Small molecule
Comparator Neostigmine Other / unclassified
Comparator Sugammadex Other / unclassified 2 mg/kg
Comparator Rocuronium Other / unclassified